Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Cushing's Disease With R-roscovitine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02160730
Recruitment Status : Terminated (NIH grant ended.)
First Posted : June 11, 2014
Results First Posted : October 29, 2021
Last Update Posted : November 4, 2021
Sponsor:
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Shlomo Melmed, MD, Cedars-Sinai Medical Center

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The investigators hypothesize that R-roscovitine will suppress pituitary corticotroph tumor ACTH production and normalize urinary free cortisol levels in patients with Cushing disease. To date, R-roscovitine has been evaluated in several Phase I and II studies and has shown early signs of anti-cancer activity in approximately 240 patients.

Condition or disease Intervention/treatment Phase
Cushings Disease Drug: R-roscovitine Phase 2

Detailed Description:
To date, R-roscovitine (seliciclib) has been evaluated in several Phase I and II studies and has shown early signs of anti-cancer activity in approximately 240 patients. Studies included a Phase I study in which single agent seliciclib was administered to patients with advanced non-small cell lung cancer (NSCLC) and two Phase IIa studies in which seliciclib was administered in combination with gemcitabine and cisplatin as first-line treatment and with docetaxel as second-line treatment in NSCLC. Seliciclib was also evaluated in a Phase I study in patients with nasopharyngeal cancer (NPC) with evidence of tumor shrinkage and concomitant reduction in copy counts of the EBV virus that is causally associated with the pathogenesis of NPC. Results from APPRAISE, a randomized discontinuation, double-blinded, placebo-controlled, Phase IIb study of oral seliciclib capsules as a monotherapy in heavily pretreated patients with NSCLC, demonstrated no difference between the seliciclib and placebo arms in progression free survival but a substantial increase in overall survival was observed (388 versus 218 days respectively (Cyclacel Pharmaceuticals press release Dec 21, 2010). Here, the investigators propose an exploratory, proof of concept clinical trial to determine if seliciclib can safely normalize urinary free cortisol levels by reducing pituitary corticotroph tumor ACTH production in patients with Cushing disease.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine
Study Start Date : May 2014
Actual Primary Completion Date : October 2018
Actual Study Completion Date : October 2018

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: R-roscovitine
• R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks.
 Drug: R-roscovitine
See Arm Description
Other Names:
  • Seliciclib
  • CYC202


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of Participants With a Normalized 24 Hour Urinary Free Cortisol After 4 Weeks [ Time Frame: Baseline, 4 weeks ]
    To evaluate the efficacy of R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks on normalizing 24 hour urinary free cortisol (24 h UFC) levels in CD patients. "Normalizing" is defined as having urine free cortisol levels within the normal range for that lab value.


Secondary Outcome Measures :
  1. Change in Mean HbA1c Levels Between Baseline and 4 Weeks [ Time Frame: Baseline, 4 Weeks ]
    HbA1c levels are measured at baseline and at study end, these are averaged across all subjects.

  2. Number of Participants With Adverse Events [ Time Frame: Baseline, 4 weeks ]
    The number of participants that experience an adverse event between baseline and study end likely related to study drug as a measure of safety and tolerability.

  3. Number of Participants That Have a Visible Change in Tumor Size [ Time Frame: Baseline, 4 weeks ]
    A visible change in tumor size as determined by the investigator after reviewing MRI reports between baseline and 4 weeks of treatment.

  4. Number of Participants That Experience Changes in Clinical Signs of Hypercortisolemia [ Time Frame: Baseline, Week 4 ]
    The number of participants that achieved a urinary free cortisol level above the upper limit of the normal range but reduced by ≥50% from baseline at week 4.

  5. Fasting Glucose at Baseline and 4 Weeks [ Time Frame: Baseline, 4 Weeks ]
    Mean change between baseline and week 4 of fasting blood glucose levels.

  6. Plasma ACTH at Baseline and 4 Weeks [ Time Frame: Baseline, 4 weeks ]
    Mean change in Plasma ACTH between baseline and 4 weeks.

  7. Change in Clinical Symptoms [ Time Frame: Baseline, 4 weeks ]
    Change in typical Cushing's syndrome clinical signs and symptoms defined by mean weight at baseline and 4 weeks.

  8. Changes in Serum Cortisol Between Baseline and 4 Weeks [ Time Frame: Baseline, 4 weeks ]
    Mean serum cortisol values at baseline and 4 weeks

  9. Change in Systolic Blood Pressure [ Time Frame: Baseline, 4 weeks ]
    Mean change in systolic blood pressure between baseline and 4 weeks.

  10. Change in Diastolic Blood Pressure [ Time Frame: Baseline, 4 weeks ]
    Mean diastolic blood pressure between baseline and 4 weeks.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Male and female patients at least 18 years old

  • Patients with confirmed pituitary origin of excess adrenocorticotropic hormone (ACTH) production:

    • Persistent hypercortisolemia established by two consecutive 24 h UFC levels at least 1.5x the upper limit of normal
    • Normal or elevated ACTH levels
    • Pituitary macroadenoma (>1 cm) on MRI OR
    • Inferior Petrosal Sinus Sampling (IPSS) central to peripheral ACTH gradient >2 at baseline and >3 after CRH stimulation
    • Recurrent or persistent Cushing disease is defined as pathologically confirmed resected pituitary ACTH-secreting tumor, and 24 hour UFC above the upper limit of normal reference range beyond post-surgical week 6
    • Patients on medical treatment for Cushing's disease the following washout periods must be completed before screening assessments are performed:
    • Inhibitors of steroidogenesis (metyrapone, ketoconazole): 2 weeks
    • Somatostatin analogs (pasireotide): 2 weeks
    • Progesterone receptor antagonist (mifepristone): 2 weeks
    • Dopamine agonists (cabergoline): 4 weeks
    • CYP3A4 strong inducers or inhibitors: varies between drugs; minimum 5-6 times the half-life of drug

Exclusion criteria:

  • Patients with compromised visual fields, and not stable for at least 6 months
  • Patients with abutment or compression of the optic chiasm on MRI and normal visual fields
  • Patients with Cushing's syndrome due to non-pituitary ACTH secretion
  • Patients with hypercortisolism secondary to adrenal tumors or nodular (primary) bilateral adrenal hyperplasia
  • Patients who have a known inherited syndrome as the cause for hormone over secretion (i.e. Carney Complex, McCune-Albright syndrome, MEN-1)
  • Patients with a diagnosis of glucocorticoid-remedial aldosteronism (GRA)
  • Patients with cyclic Cushing's syndrome defined by any measurement of UFC over the previous 1 months within normal range
  • Patients with pseudo-Cushing's syndrome, i.e. non-autonomous hypercortisolism due to overactivation of the HPA axis in uncontrolled depression, anxiety, obsessive compulsive disorder, morbid obesity, alcoholism, and uncontrolled diabetes mellitus
  • Patients who have undergone major surgery within 1 month prior to screening
  • Patients with serum K+< 3.5 while on replacement treatment
  • Diabetic patients whose blood glucose is poorly controlled as evidenced by HbA1C >8%

  • Patients who have clinically significant impairment in cardiovascular function or are at risk thereof, as evidenced by

    - Congestive heart failure (NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, clinically significant bradycardia, high grade AV block, history of acute MI less than one year prior to study entry

  • Patients with liver disease or history of liver disease such as cirrhosis, chronic active hepatitis B and C, or chronic persistent hepatitis, or patients with ALT or AST more than 1.5 x ULN, serum total bilirubin more than ULN, serum albumin less than 0.67 x LLN at screening
  • Serum creatinine > 2 x ULN
  • Patients not biochemically euthyroid

  • Patients who have any current or prior medical condition that can interfere with the conduct of the study or the evaluation of its results, such as

    • History of immunocompromise, including a positive HIV test result (Elisa and Western blot). An HIV test will not be required, however, previous medical history will be reviewed
    • Presence of active or suspected acute or chronic uncontrolled infection
    • History of, or current alcohol misuse/abuse in the 12 month period prior to screening
  • Female patients who are pregnant or lactating, or are of childbearing potential and not practicing a medically acceptable method of birth control. If a woman is participating in the trial then one form of contraception is sufficient (pill or diaphragm) and the partner should use a condom. If oral contraception is used in addition to condoms, the patient must have been practicing this method for at least two months prior to screening and must agree to continue the oral contraceptive throughout the course of the study and for 3 months after the study has ended. Male patients who are sexually active are required to use condoms during the study and for three month afterwards as a precautionary measure (available data do not suggest any increased reproductive risk with the study drugs)
  • Patients who have participated in any clinical investigation with an investigational drug within 1 month prior to screening or patients who have previously been treated with seliciclib
  • Patients with any ongoing or likely to require additional concomitant medical treatment to seliciclib for the tumor
  • Patients with concomitant treatment of strong CYP3A4 inducers or inhibitors.
  • Patients who were receiving mitotane and/or long-acting somatostatin analogs (octreotide LAR or lanreotide)
  • Patients who were receiving pasireotide or ketoconazole before study entry must complete a 2 week washout period prior to receiving seliciclib
  • Patients who have received pituitary irradiation within the last 5 years prior to the baseline visit
  • Patients who have been treated with radionuclide at any time prior to study entry
  • Patients with known hypersensitivity to seliciclib
  • Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will be unable to complete the entire study
  • Patients with presence of Hepatitis B surface antigen (HbsAg)
  • Patients with presence of Hepatitis C antibody test (anti-HCV)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02160730


Locations
Layout table for location information
United States, California
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
Sponsors and Collaborators
Shlomo Melmed, MD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Investigators
Layout table for investigator information
Principal Investigator: Shlomo Melmed, MD Cedars-Sinai Medical Center
Study Director: Ning-Ai Liu, MD, PhD Cedars-Sinai Medical Center
  Study Documents (Full-Text)

Documents provided by Shlomo Melmed, MD, Cedars-Sinai Medical Center:
Study Protocol and Statistical Analysis Plan  [PDF] September 18, 2015
Informed Consent Form: Main ICF  [PDF] May 1, 2018
Informed Consent Form: HIPAA  [PDF] May 1, 2018
Informed Consent Form: Appendix for International Subjects  [PDF] May 1, 2018

More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:
Siegel-Lakhai Wea. ASCO Proceedings, Abs 2060. 2005.
Yeo et al. J Clin Oncol 2009 27-15s (Suppl abstr 6026).

Layout table for additonal information
Responsible Party: Shlomo Melmed, MD, Sr. Vice President of Academic Affairs, Cedars-Sinai Medical Center
ClinicalTrials.gov Identifier: NCT02160730    
Other Study ID Numbers: Pro35720
1R21DK103198-01 ( U.S. NIH Grant/Contract )
First Posted: June 11, 2014    Key Record Dates
Results First Posted: October 29, 2021
Last Update Posted: November 4, 2021
Last Verified: November 2021
Keywords provided by Shlomo Melmed, MD, Cedars-Sinai Medical Center:
Cushings disease
R-roscovitine
Additional relevant MeSH terms:
Layout table for MeSH terms
ACTH-Secreting Pituitary Adenoma
Pituitary ACTH Hypersecretion
Hyperpituitarism
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Adenoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
 Neoplasms
Pituitary Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Roscovitine
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action